DA Davidson analyst Linda Bolton Weiser upgraded Medifast (MED) to Neutral from Underperform with a price target of $17, up from $16.50. With cash and investments of about $15.50 per share and no debt, the valuation “already seems to imply near zero for the remaining declining business,” so share price downside could be more limited from here, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MED:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue